EDSA earnings: next report 2026-08-14, real EPS beat/miss history, analyst consensus Buy, P/E -4.24. Updated 2026-07-23.
Edesa Biotech (EDSA) Research Hub
Edesa Biotech (EDSA) trades on NASDAQ, CA in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 4.23 USD (-10.38%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -4.24, market cap 0.05B. This hub links to the full technical, earnings and options research available for EDSA.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, CA |
| Last close | 4.23 USD (-10.38%) |
| 52-week range | 4.17 USD – 8.89 USD |
| Trend regime | Range |
| 14-day RSI | 35.2 (Bearish) |
| Trailing P/E | -4.24 |
| Market cap | 0.05B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-14 |
Available research for EDSA
Covered Call on EDSA: how it works, illustrative setup around the real 4.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on EDSA: how it works, illustrative setup around the real 4.23 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on EDSA: how it works, illustrative setup around the real 4.23 USD price, max profit/loss, breakeven and when to use it. Educational.
EDSA technical analysis: range, last 4.23 USD, RSI 35.2, 52w range 4.17 USD–8.89 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is EDSA in?
Edesa Biotech (EDSA) is classified under Healthcare (Biotechnology), listed on NASDAQ, CA.
Is EDSA in an uptrend or downtrend?
As of 2026-09-11, EDSA is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is EDSA's trailing P/E ratio?
EDSA's trailing P/E is -4.24, with a market cap of 0.05B. See the earnings research page for full valuation detail.
When does EDSA next report earnings?
EDSA is next scheduled to report earnings on 2026-08-14, with a consensus EPS estimate of -0.44 USD.